STOCK TITAN

Medicus Pharma Ltd. (MDCX) SEC Filings

MDCX NASDAQ

The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.

Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.

Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.

Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.

How Stock Titan helps

Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 64,911 common shares issuable upon exercise of warrants, updating its prospectus with its November 19, 2026 current report.

The Public Warrants have a $4.64 exercise price and expire November 15, 2029. Nasdaq lifted the deficiency under its $35 million Market Value of Listed Securities requirement after Medicus demonstrated compliance with the alternative $2.5 million shareholders’ equity requirement, giving effect to transactions described in its November 16, 2026 report. The notice makes continued compliance conditional on evidence of the equity requirement in the next periodic report for the period ending December 31, 2026; if Medicus does not evidence compliance, it may be subject to delisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.55%
Tags
prospectus
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) says Nasdaq notified it on November 18, 2026 that the $35 million market-value deficiency had been lifted after the company demonstrated compliance with the $2.5 million minimum shareholders' equity standard. The notice is conditional: Medicus must evidence continued compliance in its next periodic report for the period ending December 31, 2026.

Nasdaq based its determination on completed transactions. Medicus reported approximately $4.25 million in equity financings, comprising a $3.0 million registered direct offering and approximately $1.25 million in private placements, and exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares. The private placements included a $750,000 investment by Executive Chairman and CEO Dr. Raza Bokhari through a controlled entity. If Medicus does not evidence equity compliance in the report, it may be subject to delisting; it could appeal any such determination to a Nasdaq Hearings Panel and remains subject to Nasdaq's other continued-listing requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.55%
Tags
current report
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) shares were acquired by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, in a private placement: 436,046 common shares on November 13, 2026, at $1.72 per share, for an aggregate purchase price of $749,999.12. The purchase was funded with RBx Capital’s working capital.

RBx Capital reported beneficial ownership of 451,909 shares, or 16.2%. Dr. Bokhari reported beneficial ownership of 538,233, or 19.1%, including shares held directly, through RBx Capital and underlying options. The reported percentages use 2,788,106 issued and outstanding shares as of November 16, 2026; Dr. Bokhari’s calculation also includes 27,500 option shares in the denominator.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
ownership
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) reported that its Chief Operating Officer, Andrew Alasdair Smith, acquired 14,534 common shares on November 13, 2026, at $1.72 per share. The related footnote says Smith entered into a subscription agreement to purchase the shares in a private placement that also involved other investors under separate agreements. His reported direct holdings after the transaction were 29,243 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) Chief Medical Officer Faisal Mehmud reported acquiring 14,534 common shares at $1.72 per share on November 13, 2026. The shares were held directly, bringing his reported direct holdings to 43,946 shares. A footnote says he entered a subscription agreement to purchase the shares in a private placement alongside other investors under separate agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) director Sara R. May reported acquiring 5,813 common shares on November 13, 2026, at $1.72 per share under a subscription agreement for a private placement. Other investors participated under separate subscription agreements. Her reported direct holdings after the transaction were 5,813 shares. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) director Patrick J. Mahaffy reported acquiring 14,534 common shares on November 13, 2026, at $1.72 per share under a subscription agreement in a private placement. He reported direct holdings of 15,243 shares after the transaction. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) director Larry Kaiser reported acquiring 14,534 common shares on November 13, 2026, at $1.72 per share. A footnote says Kaiser entered a subscription agreement to purchase the shares in a private placement in which other investors also participated under separate agreements. He held 14,542 common shares directly after the transaction. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) director Robert J. Ciaruffoli reported acquiring 72,674 common shares. A footnote says he entered into a subscription agreement on November 13, 2026, to purchase the shares for $1.72 per share in a private placement. His reported direct holdings after the transaction were 72,924 shares. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
Rhea-AI Summary

Edward J. Brennan reported acquisition or exercise transactions in this Form 4 filing. Medicus Pharma Ltd. reported that SVP, Medical Affairs Edward J. Brennan entered a private-placement subscription agreement to purchase 14,534 common shares at $1.72 per share on November 13, 2026. His reported direct holdings following the transaction were 28,029 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider

FAQ

How many Medicus Pharma Ltd. (MDCX) SEC filings are available on StockTitan?

StockTitan tracks 189 SEC filings for Medicus Pharma Ltd. (MDCX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Medicus Pharma Ltd. (MDCX)?

The most recent SEC filing for Medicus Pharma Ltd. (MDCX) was filed on November 19, 2026.